Mankind Pharma Ltd's initial public offer (IPO) will open for subscription on Tuesday, April 25, and close on Thursday, April 27. The company has fixed the price band at ₹1,026 to ₹1,080 per equity share for the proposed initial public offer.
The public offering, which has a face value of ₹1 per equity share, consists of a pure offer-for-sale (OFS) of 40,058,844 equity shares by promoters and other existing shareholders.
The company intends to raise a maximum of ₹4,326.36 crore at the upper band of the price range.
The OFS comprises about 37.1 lakh shares by Ramesh Juneja, 35.1 lakh shares by Rajeev Juneja, 28 lakh shares by Sheetal Arora, 174.1 lakh by Cairnhill CIPEF Ltd, 26.2 lakh shares by Cairnhill CGPE Ltd, 99.6 lakh shares by Beige Ltd, and 50,000 shares by Link Investment Trust.
The offer is being made through the book-building process, in which not less than 15% of the offer must be made available to non-institutional investors and not less than 35% of the offer must be made available to retail individual investors. Not more than 50% of the offer may be allocated to qualified institutional buyers.
The issue's book-running lead managers (BRLM) are Kotak Mahindra Capital Company Ltd, Axis Capital Ltd, IIFL Securities Ltd, Jefferies India Private Ltd, and JP Morgan India Private Ltd.
KFin Technologies Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE on Monday, May 8.
Mankind Pharma Limited develops, manufactures, and markets a variety of consumer healthcare items in addition to pharmaceutical formulations for a range of acute and chronic therapeutic areas.
The company operates in India in a number of acute and chronic therapeutic areas, including respiratory, neuro/CNS, cardiovascular, gastrointestinal, anti-diabetic, and anti-infectives.